Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers

BACKGROUND: The anti-SLAMF7 monoclonal antibody, elotuzumab (elo), plus lenalidomide (len) and dexamethasone (dex) is approved for relapsed/refractory MM in the U.S. and Europe. Recently, a small phase 2 study demonstrated an advantage in progression-free survival (PFS) for elo plus pomalidomide (po...

Descripción completa

Detalles Bibliográficos
Autores principales: Hose, Dorothea, Schreder, Martin, Hefner, Jochen, Bittrich, Max, Danhof, Sophia, Strifler, Susanne, Krauth, Maria-Theresa, Schoder, Renate, Gisslinger, Bettina, Einsele, Hermann, Gisslinger, Heinz, Knop, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810646/
https://www.ncbi.nlm.nih.gov/pubmed/32683487
http://dx.doi.org/10.1007/s00432-020-03323-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810646/
https://www.ncbi.nlm.nih.gov/pubmed/32683487
http://dx.doi.org/10.1007/s00432-020-03323-6

Ejemplares similares